Medical experts say current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones will not help healthcare or patient welfare. Since the early 2000s, numerous articles and reports have claimed that the pipeline for new drugs will soon run dry, write Donald Light from the University of Medicine and Dentistry of New Jersey and Joel Lexchin from York University in Toronto. Yet data indicate that the ...
via Medindia Health News
More READ
No comments:
Post a Comment